What does ENDRA Life Sciences do?
ENDRA Life Sciences Inc. is a development-stage medical-technology company listed on the Nasdaq Capital Market under the ticker NDRA. Its core asset is Thermo-Acoustic Enhanced UltraSound, or TAEUS, a platform intended to measure tissue composition by combining radio-frequency energy with ultrasound detection. The immediate commercial target is quantitative liver-fat measurement for steatotic liver disease, metabolic-disease management, and potential use in selecting and monitoring patients receiving GLP-1 therapies. ENDRA’s official TAEUS overview explains the basic concept: radio-frequency pulses are absorbed by tissue, generate acoustic signals, and are translated by proprietary algorithms into a measure of liver fat.
| Research item | ENDRA-specific answer | Why it matters |
|---|---|---|
| Core product | TAEUS liver device designed to complement conventional B-mode ultrasound | The value proposition depends on adding quantitative information without requiring MRI-scale capital equipment. |
| Primary use case | Point-of-care measurement and monitoring of liver fat | A clinically useful, repeatable metric could support screening, treatment selection, and longitudinal monitoring. |
| Regulatory status | CE-marked in Europe; not approved for U.S. commercial sale | European certification has not yet translated into reported revenue, while U.S. commercialization requires an FDA De Novo grant. |
| Operating stage | Development-stage and pre-revenue through March 31, 2026 | Conventional revenue-multiple analysis is premature; liquidity, regulatory milestones, and transaction execution dominate. |
How does the technology differ from ordinary ultrasound?
Conventional ultrasound primarily maps how sound waves scatter from tissue structure. TAEUS instead seeks to map how tissue absorbs pulsed radio-frequency energy, with the resulting thermoacoustic signal detected at the skin. ENDRA’s 2025 Form 10-K describes four subsystems: energy generation, energy delivery, signal detection, and computation/display. The company’s first-generation system is designed to sit beside a patient bed and use a conventional ultrasound image to guide placement.
Which customers would use TAEUS?
How would ENDRA make money if TAEUS commercializes?
ENDRA does not yet have a functioning revenue stream. Its intended model is a low-barrier, multi-year subscription with monthly recurring revenue, supplemented over time by direct sales, channel relationships, and potential licensing to ultrasound or thermoablation equipment manufacturers. This planned architecture matters because it attempts to replace a large upfront medical-capital purchase with a recurring payment tied to clinical use and workflow adoption.
What are the prospective revenue streams?
| Prospective stream | Pricing logic | Main dependency |
|---|---|---|
| TAEUS subscriptions | Monthly recurring payment under a multi-year arrangement | Regulatory clearance, clinical proof, customer ROI, and reliable manufacturing |
| Direct commercial placements | System access bundled with service, training, or software | A rebuilt sales organization and sufficient working capital |
| Channel partnerships | Distributor or commercial-partner economics | Partners willing to support a new diagnostic category |
| OEM licensing | License fees, royalties, or development payments | Technical integration, intellectual-property protection, and partner commitment |
Which cost drivers determine whether the model can scale?
The subscription model can only become attractive if system manufacturing cost, installation cost, service burden, clinical-support expense, and customer-acquisition cost remain below the present value of recurring payments. ENDRA relies on suppliers and contract manufacturers rather than owning a vertically integrated factory. That reduces fixed manufacturing investment but increases dependency on third-party quality systems, component availability, and production scheduling. It also means gross margin cannot be evaluated from historical statements because the company reported no revenue and no cost of goods sold in either the first quarter of 2026 or the comparable 2025 quarter.
What does the latest reported period show?
The latest full financial statements are in ENDRA’s Form 10-Q for the quarter ended March 31, 2026. They show a company with no commercial revenue, a sharply reduced cash balance, and expenses increasingly shaped by stock compensation and corporate activity rather than selling activity.
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Revenue | $0 | $0 | Commercial validation remains absent. |
| Research and development | $0.78M | $0.53M | Up 47%, reflecting product-development and third-party work. |
| Sales and marketing | $0.004M | $0.069M | Down 94%, consistent with restructuring and limited commercial activity. |
| General and administrative | $1.39M | $0.87M | Up 60%; Q1 2026 included $0.57M of stock compensation. |
| Operating cash used | $1.12M | $1.29M | Cash burn improved, but remained large relative to quarter-end cash. |
| Stockholders’ equity | $1.79M | $1.75M | Below Nasdaq’s $2.5M threshold before the May financing. |
Where did Q1 2026 spending go?
How should the cash-flow statement be read?
The quarter-end cash figure was therefore not a viable stand-alone runway. ENDRA partly funded the quarter by selling $0.45M of digital assets and raising $0.26M through common-stock issuance. The company explicitly stated that it needed additional capital to fund the following twelve months and that substantial doubt existed about its ability to continue as a going concern. The May 2026 private placement changed the immediate liquidity picture, but it did not create operating self-sufficiency.
Which turning points explain ENDRA’s current position?
ENDRA’s history is best understood as a sequence of technology validation, regulatory delay, repeated financing, and an eventual strategic pivot. The most important events are those that still affect the company’s assets, cost structure, and control of the public listing.
A strategic timeline from platform development to proposed combination
-
2007ENDRA was incorporated in Delaware, establishing the corporate vehicle that later developed the TAEUS platform.
-
2020The TAEUS fatty-liver imaging system received a CE mark. This created European market access, but the company still did not report commercial revenue through Q1 2026.
-
2023ENDRA submitted an FDA De Novo request supported by clinical comparisons with MRI-PDFF, making U.S. regulatory clearance the central value milestone.
-
2024The FDA closed the original De Novo application after requesting additional clinical, device-testing, and cybersecurity information. Cost reductions and leadership changes followed.
-
2025ENDRA adopted a digital-asset treasury strategy and acquired HYPE tokens, adding asset-price and accounting volatility to a medical-device balance sheet.
-
March 2026The board initiated a strategic-alternatives review and reduced headcount, signaling that preservation of public-company value had become as important as advancing TAEUS.
-
June 2026ENDRA signed a proposed merger with Noble Africa, the holding platform for Renergen, potentially transforming NDRA from a thermoacoustic-medical-device company into a helium-focused public company.
What gives TAEUS a potential competitive advantage?
TAEUS is not protected by an established commercial network, installed-base leadership, or demonstrated switching costs. Its potential moat is technological and regulatory: a differentiated way to quantify liver fat at the point of care, supported by a broad patent portfolio and designed to work alongside existing ultrasound workflows. The word “potential” is essential because the company has not yet converted those resources into sales.
How defensible is the intellectual-property position?
The portfolio covers signal generation, radio-frequency delivery, acoustic detection, integration with conventional ultrasound, and signal-processing algorithms. This breadth can raise the cost of direct imitation. Yet patents do not prove clinical utility, reimbursement, manufacturability, or freedom from design-around competition. Their value depends on the company retaining enough resources to maintain, enforce, and commercialize them.
What would turn the technology into a real moat?
Who competes with ENDRA, and where is it positioned?
ENDRA says it is the only company developing radio-frequency-based thermoacoustic ultrasound products, but its economic competition is much broader than direct technology duplication. A customer can choose MRI-PDFF, conventional ultrasound, elastography, CT in selected settings, blood-based markers, biopsy, or no additional test. Large imaging companies also have greater R&D budgets, installed bases, service organizations, and regulatory capacity.
Which alternatives create the strongest pressure?
| Competitor or substitute | Current advantage | ENDRA’s intended differentiation | Strategic pressure |
|---|---|---|---|
| MRI and MRI-PDFF systems | Established quantitative reference and broad clinical acceptance | Lower-cost, point-of-care measurement without MRI infrastructure | TAEUS must demonstrate comparable decision usefulness, not merely lower cost. |
| GE HealthCare, Philips, Siemens Healthineers, Canon, Fujifilm | Installed base, service networks, regulatory resources, and bundled imaging portfolios | A specialized thermoacoustic add-on with proprietary algorithms | Large vendors could develop alternatives, partner, or make integration difficult. |
| Conventional ultrasound and elastography | Familiar workflow and widespread availability | Direct liver-fat quantification rather than structural or stiffness proxies | Clinicians may prefer “good enough” existing tools unless TAEUS changes decisions. |
| Blood tests and biopsy | Blood tests are simple; biopsy provides tissue diagnosis | Non-invasive repeated measurement at the point of care | Reimbursement and clinical guidelines determine whether a new imaging step is added. |
This is a high-rivalry market with powerful suppliers, powerful health-system buyers, and meaningful substitution. ENDRA’s strongest strategic path would likely involve partnerships rather than trying to match the sales and service scale of multinational imaging vendors. Conversely, dependence on partners can reduce bargaining power and delay commercialization if counterparties assign the project a lower priority.
How strong are liquidity, capital structure, and governance?
ENDRA’s financial health is weak on a stand-alone operating basis. The company has accumulated losses, no revenue, a going-concern warning, repeated equity issuance, a warrant liability, and a history of reverse stock splits. The 2025 annual results provide the most useful baseline for how aggressively costs were reduced before the 2026 strategic transaction process.
Did the 2025 restructuring reduce annual burn?
| Annual metric | FY2025 | FY2024 | Research implication |
|---|---|---|---|
| Research and development | $1.85M | $3.19M | Lower spend preserved cash but can slow engineering and clinical progress. |
| Sales and marketing | $0.19M | $0.57M | The commercial organization was substantially reduced. |
| General and administrative | $3.72M | $7.06M | Public-company and financing costs remained the largest annual category. |
| Net loss | $7.03M | $11.51M | Loss narrowed, but no revenue base existed to fund operations. |
| Cash | $0.76M | $3.23M | Cash declined 76.4% during FY2025. |
| Digital assets | $2.01M | $0 | Treasury value became exposed to HYPE-token volatility. |
Who owns the stock, and what does governance signal?
The ownership profile is concentrated in a few financing-related positions rather than a founder-controlled operating franchise. ENDRA’s 2025 Form 10-K reports ownership as of March 31, 2026 and the 2025 definitive proxy statement provides the preceding annual-meeting context.
| Holder or group | Reported position | Source period | Why it matters |
|---|---|---|---|
| Anthony DiGiandomenico | 70,890 common shares; 5.7% | March 31, 2026 | A director’s stake largely reflects participation in the October 2025 financing. |
| Directors and executive officers as a group | 70,922 common shares; 5.7% | March 31, 2026 | Economic alignment is meaningful but not controlling. |
| Juan R. Rivero | 17.488 Series A preferred shares; 100% of that class | March 31, 2026 | The preferred class was economically small and represented roughly one common-equivalent vote at the 2025 record date. |
| Board structure | 4 directors; 3 designated independent | FY2025 filing | Independent committees oversee audit, compensation, and nominations, but transaction complexity raises oversight demands. |
On May 27, 2026, ENDRA entered a private placement for approximately $3.8M of gross proceeds, issuing 578,387 shares or pre-funded warrants plus warrants for up to 1,156,774 shares at a $6.57 exercise price. The financing Form 8-K shows why share-count and fully diluted ownership can change rapidly. This financing helped the company regain Nasdaq’s minimum-equity compliance, but the July notice also placed ENDRA under a one-year discretionary panel monitor.
The proposed Noble Africa merger could redefine the entire investment case
On June 25, 2026, ENDRA signed a merger agreement with Noble Africa LLC, an intermediate holding company for Renergen Limited. The merger Form 8-K states that Noble Africa would merge with an ENDRA subsidiary and survive as a wholly owned subsidiary of ENDRA. After closing, the combined company plans to operate as Noble Africa Inc. and apply to trade under the ticker NOBA. This is not a normal bolt-on acquisition; it is a proposed change in the identity, asset base, governance, and valuation framework of the public company.
What must happen before the transaction changes NDRA?
The transaction remains subject to closing conditions, stockholder approval, securities-registration and proxy materials, Nasdaq listing requirements, the concurrent financing, and other customary conditions. Until closing, ENDRA remains NDRA and its legacy financial statements remain those of a pre-revenue medical-device developer. The company’s official transaction announcement says the planned approximately $50M financing includes approximately $30M from other investors and $0.75M from certain ASP Isotopes directors and management.
What opportunities and risks should researchers monitor?
ENDRA now has two overlapping opportunity sets and two overlapping risk sets: the legacy medical-device platform and the proposed transaction. The company’s March 2026 strategic-alternatives announcement marked the bridge between them.
Which developments could improve or weaken the story?
The July 2026 Nasdaq compliance Form 8-K confirms that ENDRA regained compliance after the financing. However, any new deficiency during the monitoring period may be harder to cure because the company would not receive the usual compliance-plan or cure-period process described in that notice.
What matters most for valuation and the final takeaway?
A conventional DCF assumes a reasonably forecastable operating business. ENDRA does not currently meet that condition. The legacy business has no revenue history, no demonstrated gross margin, an unfinished FDA pathway, and uncertain funding for commercialization. The proposed merger introduces a second valuation regime based on transaction probability, exchange mechanics, financing, high-vote control, and the economics of Renergen’s helium assets.
Which variables belong in an ENDRA valuation model?
| Valuation driver | Legacy TAEUS case | Proposed merger case | Modeling treatment |
|---|---|---|---|
| Probability of success | FDA, clinical, manufacturing, and adoption milestones | Closing conditions and financing completion | Use explicit scenario probabilities rather than one blended forecast. |
| Revenue onset | Timing of first subscriptions or licensing revenue | Operating profile of the helium platform after closing | Do not extrapolate from zero revenue without milestone gates. |
| Margin structure | Subscription pricing less manufacturing, service, and commercial costs | Project development, production, logistics, and financing economics | Build separate unit-economics and capital-intensity assumptions. |
| Dilution | Existing shares, options, warrants, and future funding | Transaction shares, financing securities, and dual-class voting rights | Value per fully diluted share, not only enterprise value. |
| Terminal value | Patent life, reimbursement, competition, and product obsolescence | Resource life, helium pricing, execution, and replacement capital | Use different terminal assumptions for each business identity. |
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.